Russell Patmore

5.0k total citations · 3 hit papers
71 papers, 3.3k citations indexed

About

Russell Patmore is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Russell Patmore has authored 71 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pathology and Forensic Medicine, 35 papers in Oncology and 25 papers in Genetics. Recurrent topics in Russell Patmore's work include Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (12 papers). Russell Patmore is often cited by papers focused on Lymphoma Diagnosis and Treatment (39 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Viral-associated cancers and disorders (12 papers). Russell Patmore collaborates with scholars based in United Kingdom, Norway and Belarus. Russell Patmore's co-authors include Eve Roman, Debra Howell, Andrew Jack, Alexandra Smith, Simon Crouch, A. G. Smith, Sharon Barrans, Roger G. Owen, Martin Howard and Anne C Garry and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Russell Patmore

67 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

2011 486 citations A. G. Smith, Debra Howell et al. profile →
Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network

2015 282 citations Simon Crouch, Dan Painter et al. profile →
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report

2020 260 citations Stuart Lacy, Sharon Barrans et al. Blood profile →

Peers

Countries citing papers authored by Russell Patmore

Since Specialization

Citations

This map shows the geographic impact of Russell Patmore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Russell Patmore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Russell Patmore more than expected).

Fields of papers citing papers by Russell Patmore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Russell Patmore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Russell Patmore. The network helps show where Russell Patmore may publish in the future.

Co-authorship network of co-authors of Russell Patmore

This figure shows the co-authorship network connecting the top 25 collaborators of Russell Patmore. A scholar is included among the top collaborators of Russell Patmore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Russell Patmore. Russell Patmore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	COVID ‐19‐related mortality in a real‐world cohort of 18 883 patients with premalignant and malignant haematological neoplasms: An analysis from the UK 's Haematological Malignancy Research Network 2025 ·British Journal of Haematology ·Alexandra Smith, Clare Frobisher, Abraham Varghese, Andy C. Rawstron, Simon Crouch, Debra Howell, Adele K. Fielding, Kirstine Eastick, Catherine Cargo, Cathy Burton, Gordon Cook, Nicholas Easom, Reuben Tooze, Patrick Lillie, Eve Roman, Russell Patmore	0
2	Experiences and preferences for psychosocial support: a qualitative study exploring the views of patients with chronic haematological cancers 2023 ·BMJ Open ·Rebecca Sheridan, Dorothy McCaughan, (unknown), Eve Roman, Alexandra Smith, Russell Patmore, Debra Howell	4
3	Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research Network 2023 ·Cancer Epidemiology ·Maxine Lamb, Daniel Painter, Debra Howell, Sharon Barrans, Catherine Cargo, Ruth de Tute, Reuben Tooze, Cathy Burton, Russell Patmore, Eve Roman, Alexandra Smith	10
4	Patient perspectives of ‘Watch and Wait’ for chronic haematological cancers: Findings from a qualitative study 2023 ·European Journal of Oncology Nursing ·Dorothy McCaughan, Eve Roman, Rebecca Sheridan, (unknown), Alexandra Smith, Russell Patmore, Debra Howell	5
5	Treatment decision making (TDM): a qualitative study exploring the perspectives of patients with chronic haematological cancers 2022 ·BMJ Open ·Dorothy McCaughan, Eve Roman, Alexandra Smith, Russell Patmore, Debra Howell	14
6	Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network 2022 ·Blood Advances ·Simon Crouch, Daniel Painter, Sharon Barrans, Eve Roman, Philip Beer, Susanna L. Cooke, Paul Glover, (unknown), Nichola Webster, Stuart Lacy, Camilo Ruiz, Peter J. Campbell, Daniel J. Hodson, Russell Patmore, Cathy Burton, Alexandra Smith, Reuben Tooze	17
7	Incurable but treatable: Understanding, uncertainty and impact in chronic blood cancers—A qualitative study from the UK’s Haematological Malignancy Research Network 2022 ·PLoS ONE ·Debra Howell, Dorothy McCaughan, Alexandra Smith, Russell Patmore, Eve Roman	26
8	Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort 2021 ·BMJ Open ·Maxine Lamb, Alexandra Smith, Daniel Painter, Eleanor Kane, (unknown), Robert Newton, Debra Howell, Gordon Cook, Ruth de Tute, Andy C. Rawstron, Russell Patmore, Eve Roman	6
9	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report breakdown → 2020 ·Blood ·Stuart Lacy, Sharon Barrans, Philip Beer, Daniel Painter, Alexandra Smith, Eve Roman, Susanna L. Cooke, Camilo Ruiz, Paul Glover, (unknown), Nichola Webster, Peter J. Campbell, Reuben Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J. Hodson	260
10	Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial 2020 ·SHILAP Revista de lepidopterología ·Elizabeth H. Phillips, Catherine Burton, Amy A. Kirkwood, Sharon Barrans, (unknown), Simon Rule, Russell Patmore, Ruth Pettengell, Kirit M. Ardeshna, Silvia Montoto, Shankara Paneesha, Laura Clifton‐Hadley, David C. Linch, Andrew McMillan	6
11	The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK’s population-based Haematological Malignancy Research Network 2019 ·Cancer Epidemiology ·Eleanor Kane, Daniel Painter, Alexandra Smith, Simon Crouch, Steven Oliver, Russell Patmore, Eve Roman	12
12	Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma 2018 ·British Journal of Haematology ·Rory McCulloch, Alexandra Smith, (unknown), Russell Patmore, Simon Rule	1
13	Myeloma: Patient accounts of their pathways to diagnosis 2018 ·PLoS ONE ·Debra Howell, Ruth I. Hart, Alexandra Smith, Una Macleod, Russell Patmore, Gordon Cook, Eve Roman	29
14	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN) 2018 ·British Journal of Haematology ·Alexandra Smith, Eve Roman, Simon Appleton, Debra Howell, Rod Johnson, Cathy Burton, Russell Patmore	32
15	Forecasting Treatment Costs of Follicular Lymphoma: A Population-Based Discrete Event Simulation 2016 ·Value in Health ·(unknown), Eline Aas, A. G. Smith, Simon Crouch, Eve Roman, Russell Patmore	1
16	Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma 2015 ·Cancer Epidemiology ·Alexandra Smith, Simon Crouch, Debra Howell, Cathy Burton, Russell Patmore, Eve Roman	38
17	Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort 2014 ·BMJ Open ·A. G. Smith, Dan Painter, Debra Howell, Paul Evans, Graeme Smith, Russell Patmore, Andrew Jack, Eve Roman	42
18	Long-Term Medical Costs and Life Expectancy of Acute Myeloid Leukemia: A Probabilistic Decision Model 2014 ·Value in Health ·Han‐I Wang, Eline Aas, Debra Howell, Eve Roman, Russell Patmore, Andrew Jack, Alexandra Smith	18
19	Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab 2010 ·Journal of Clinical Oncology ·Sharon Barrans, Simon Crouch, Alex Smith, Kathryn Turner, Roger G. Owen, Russell Patmore, Eve Roman, Andrew Jack	402
20	The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research 2009 ·British Journal of Haematology ·Alexandra Smith, Eve Roman, Debra Howell, Richard A. Jones, Russell Patmore, Andrew Jack	111

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact